Phase 3 Readout~month
Phase 3 Topline: A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chron
- Drug
- barzolvolimab
- Indication
- Chronic Spontaneous Urticaria
Other upcoming events for CLDX
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzol
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.